Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?

Circulation - 11 Apr 2000

Benhorin J, Taub R, Goldmit M, Kerem B, Kass R S, Windman I, Medina A

Abstract excerpt

BACKGROUND: Mutations in the cardiac sodium channel gene (SCN5A) can cause one variant of the congenital long-QT syndrome. The effects of some of these mutations on the alpha-subunit channel properties can be blocked by type Ib antiarrhythmic drugs. Recently, we have described a new SCN5A mutation (D1790G) that affects the channel properties in a manner suggesting that sodium blockers of the Ib type will be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Electrocardiography
Share to Flecainide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Injections, Intravenous

Share to Long QT Syndrome

Share to NAV1.5 Voltage-Gated Sodium Channel

Share to Sodium Channels

Source

Identifiers

PMID: 10758053
DOI: 10.1161/01.cir.101.14.1698

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?PMID 10758053Read ↗

Mutations in cardiac sodium channels: clinical implications.Semantic proximity Read ↗

Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.Semantic proximity Read ↗

A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.Semantic proximity Read ↗

Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.Semantic proximity Read ↗

Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.Semantic proximity Read ↗

Long-term flecainide therapy in type 3 long QT syndrome.Semantic proximity Read ↗

A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.Semantic proximity Read ↗

Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome.Semantic proximity Read ↗

Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide.Semantic proximity Read ↗

Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.Semantic proximity Read ↗

In vivo studies of Scn5a+/- mice modeling Brugada syndrome demonstrate both conduction and repolarization abnormalities.Semantic proximity Read ↗

Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.